Ozempic is not FDA-approved for weight loss. Its approved uses are limited to adults with type 2 diabetes: improving blood sugar control, reducing cardiovascular risk, and protecting kidney function. Weight loss is a well-documented effect of the drug, but the FDA has never listed it as an official indication on the Ozempic label.
This distinction matters more than it might seem, because it affects what your doctor can prescribe, what your insurance will cover, and which version of the drug you actually need.
What Ozempic Is Approved For
The FDA has approved Ozempic for three specific uses, all in adults with type 2 diabetes. First, it’s approved alongside diet and exercise to improve blood sugar control. Second, it’s approved to reduce the risk of major cardiovascular events like heart attack and stroke in people who also have established heart disease. Third, as of a recent label update, it’s approved to slow kidney decline and reduce the risk of kidney failure in people with both type 2 diabetes and chronic kidney disease.
The drug’s prescribing information does note that semaglutide “reduces body weight” as part of how it works in the body. But there’s a significant gap between a drug causing weight loss as a side effect and the FDA formally approving it for that purpose. Formal approval requires dedicated clinical trials showing the drug is safe and effective specifically for weight management, at a dose tested for that goal.
Wegovy Is the FDA-Approved Version for Weight Loss
Here’s where people often get confused: Ozempic and Wegovy contain the exact same active ingredient, semaglutide. They’re both made by Novo Nordisk and delivered as weekly injections. The key difference is the dose and the approved use.
Ozempic maxes out at 2 mg per week. Wegovy goes up to 2.4 mg per week and is specifically approved for reducing excess body weight in adults with obesity, or in adults who are overweight and have at least one weight-related health condition like high blood pressure, high cholesterol, or type 2 diabetes. In clinical trials, people taking the 2.4 mg dose lost an average of 13.9% of their body weight over 52 weeks, compared to 2.7% in the placebo group. That higher dose is part of why Wegovy exists as a separate product rather than simply expanding Ozempic’s label.
How Semaglutide Causes Weight Loss
Semaglutide mimics a hormone your gut naturally releases after eating. This hormone signals your brain to feel full, and semaglutide amplifies that signal in several ways. It suppresses appetite by acting on brain regions that control hunger. It slows the rate at which food leaves your stomach, so you feel satisfied longer after meals. And it enhances the feeling of fullness (satiety) that normally follows eating, which leads most people to simply eat less without feeling like they’re white-knuckling a diet.
These effects happen at both the Ozempic and Wegovy dose ranges, which is why people taking Ozempic for diabetes frequently lose weight as a bonus. But the higher Wegovy dose produces more pronounced weight loss on average.
Off-Label Prescribing for Weight Loss
Doctors can legally prescribe Ozempic off-label for weight loss. Off-label prescribing is common across medicine and perfectly legal. It means a doctor is using their clinical judgment to prescribe a drug for a purpose the FDA hasn’t formally approved. Many providers have done exactly this with Ozempic, particularly when Wegovy has been difficult to find due to ongoing supply shortages.
The practical problem is insurance. Most insurers will not cover Ozempic unless you have a type 2 diabetes diagnosis. The National Association of Insurance Commissioners notes that while providers may prescribe these drugs off-label for obesity, coverage usually requires a diabetes diagnosis. Some employers go further and exclude GLP-1 drugs from their health plans entirely. Medicare, by law, cannot cover weight loss medications at all. Without insurance, the out-of-pocket cost can run over $1,000 per month.
Safety Considerations
Whether prescribed as Ozempic or Wegovy, semaglutide carries real risks. The FDA requires a boxed warning (the most serious type) about the risk of thyroid tumors. Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during the dose-escalation period when you’re gradually increasing to your target dose.
In 2025, the FDA issued a warning letter to Novo Nordisk for a promotional video that the agency determined was “false or misleading” because it understated the drug’s risks. The letter specifically called out the video for suggesting that safety concerns were “overhyped” and for omitting several serious risks. The FDA described the drugs as having “multiple serious, potentially life-threatening risks.” This doesn’t mean the drugs are unsafe when used appropriately, but it underscores that semaglutide is not a casual lifestyle medication.
The Bottom Line on Approval Status
If your goal is weight loss and you don’t have type 2 diabetes, Wegovy is the version of semaglutide that was tested, dosed, and approved for that purpose. Ozempic can produce weight loss, and doctors can prescribe it off-label, but you’re likely to face insurance barriers and you’ll be taking a lower maximum dose than what the weight-loss trials used. If you do have type 2 diabetes and want both blood sugar control and weight loss, Ozempic may accomplish both goals within its approved use, and your insurance is far more likely to cover it.